Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458653 · ClinicalTrials.gov registry record · Phase 1
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00458653 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 45 participants.
The verdict
NCT00458653, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The main purpose of this study is to test the safety and determine the type and severity of any side effects of the Dendritic Cell Fusion Vaccine given in combination with an autologous transplant for patients with multiple myeloma. Autologous stem cell transplantation is a standard therapy for multiple myeloma that is often successful in significantly decreasing the amount of cancer. However, it is not a cure because at some point the multiple myeloma generally begins to grow again. Cancer vaccines are investigational agents that try to stimulate the immune system to recognize and fight against cancer cells. One type of cancer vaccine uses an immune stimulating cell of the body known as a dendritic cell. Research has shown that these dendritic cells can stimulate an immune response against the tumor.
Interventions
- BIOLOGICAL Dendritic Cell Tumor Fusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-04 |
| Est. Completion | 2020-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458653
The ClinicalTrials.gov registry entry for NCT00458653 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dendritic Cell Tumor Fusion is the first listed.
NCT00458653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458653 about?
NCT00458653 is a clinical study titled "Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma". The main purpose of this study is to test the safety and determine the type and severity of any side effects of the Dendritic Cell Fusion Vaccine given in combination with an autologous transplant for patients with multiple myeloma. Autologous stem cell transplantation is a standard therapy for mult...
What is the current status of trial NCT00458653?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2005-04. Estimated completion is 2020-07.
What interventions are being tested in trial NCT00458653?
The interventions under investigation include: Dendritic Cell Tumor Fusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT00458653?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.